PriceTargets.com logo

Arrowhead Pharmaceuticals - ARWR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $45.33
  • Forecasted Upside: 142.29%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$18.71 As of 11/20/2024 01:00 AM ET
▲ +0.11 (0.59%)

This chart shows the closing price for ARWR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arrowhead Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARWR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARWR

Analyst Price Target is $45.33
▲ +142.29% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $45.33, with a high forecast of $62.00 and a low forecast of $27.00. The average price target represents a 142.29% upside from the last price of $18.71.

This chart shows the closing price for ARWR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Arrowhead Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/8/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$62.00 ➝ $62.00
9/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/12/2024B. RileyReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
7/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
7/17/2024Chardan CapitalReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
7/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $60.00
6/26/2024Chardan CapitalReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/5/2024The Goldman Sachs GroupInitiated CoverageNeutral$31.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/3/2024Chardan CapitalReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/13/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$36.00 ➝ $27.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
5/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
2/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
2/7/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$34.00 ➝ $36.00
2/7/2024CitigroupBoost TargetNeutral ➝ Neutral$33.00 ➝ $34.00
2/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00
1/16/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00
1/2/2024Bank of AmericaBoost TargetBuy ➝ Buy$29.00 ➝ $37.00
12/4/2023Bank of AmericaInitiated CoverageBuy$29.00
11/30/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00
11/30/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $37.00
9/19/2023CitigroupInitiated CoverageNeutral$33.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/8/2023Chardan CapitalReiterated RatingBuy ➝ Buy$60.00
8/8/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$60.00
8/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$79.00 ➝ $47.00
7/21/2023TD CowenInitiated CoverageOutperform
7/20/2023B. RileyReiterated RatingBuy ➝ Buy$55.00
6/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
6/2/2023Piper SandlerBoost Target$52.00 ➝ $59.00
5/12/2023Leerink PartnersDowngradeOutperform ➝ Market Perform
5/12/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$40.00
5/3/2023500.comReiterated RatingReiterates
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$80.00
4/12/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform
4/12/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$21.00 ➝ $35.00
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$27.00
2/10/2023HC WainwrightReiterated RatingBuy$90.00
2/10/2023Chardan CapitalReiterated RatingBuy$60.00
2/8/2023B. RileyLower TargetBuy$59.00 ➝ $55.00
2/7/2023Royal Bank of CanadaLower TargetOutperform$83.00 ➝ $77.00
2/7/2023Piper SandlerLower TargetOverweight$55.00 ➝ $52.00
2/7/2023Robert W. BairdLower TargetOutperform$60.00 ➝ $58.00
1/10/2023Chardan CapitalLower Target$82.00 ➝ $60.00
1/9/2023Piper SandlerLower Target$64.00 ➝ $55.00
12/6/2022HC WainwrightLower TargetBuy$110.00 ➝ $90.00
11/30/2022The Goldman Sachs GroupReiterated RatingBuy$65.00 ➝ $66.00
11/30/2022B. RileyLower TargetBuy$65.00 ➝ $59.00
11/29/2022Jefferies Financial GroupLower TargetBuy$92.00 ➝ $75.00
11/29/2022Morgan StanleyLower TargetEqual Weight$41.00 ➝ $37.00
11/29/2022Leerink PartnersLower TargetMarket Perform$33.00 ➝ $31.00
11/10/2022Leerink PartnersBoost TargetMarket Perform$32.00 ➝ $33.00
11/9/2022Piper SandlerLower TargetOverweight$72.00 ➝ $64.00
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$41.00
8/8/2022The Goldman Sachs GroupBoost TargetBuy$58.00 ➝ $65.00
8/5/2022Chardan CapitalBoost Target$80.00 ➝ $82.00
7/14/2022HC WainwrightReiterated RatingBuy$110.00
6/3/2022HC WainwrightBoost TargetBuy$100.00 ➝ $110.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$90.00 ➝ $66.00
5/11/2022Piper SandlerLower Target$89.00 ➝ $72.00
5/11/2022Robert W. BairdUpgradeNeutral ➝ Outperform$71.00 ➝ $60.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/23/2022HC WainwrightReiterated RatingBuy$100.00
2/8/2022HC WainwrightReiterated RatingBuy$100.00
2/3/2022Leerink PartnersLower TargetMarket Perform$46.00 ➝ $36.00
1/28/2022Leerink PartnersBoost TargetMarket Perform$45.00 ➝ $46.00
1/19/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy
11/23/2021Leerink PartnersBoost TargetMarket Perform$44.00 ➝ $45.00
8/10/2021HC WainwrightBoost TargetBuy$95.00 ➝ $100.00
8/6/2021Chardan CapitalLower TargetBuy$97.00 ➝ $94.00
7/2/2021HC WainwrightReiterated RatingBuy$95.00
7/2/2021Piper SandlerLower TargetOverweight$109.00 ➝ $89.00
6/27/2021Leerink PartnersReiterated RatingHold
6/21/2021Piper SandlerBoost TargetOverweight ➝ Overweight$99.00 ➝ $109.00
2/8/2021CitigroupBoost Target$90.00 ➝ $110.00
2/8/2021B. RileyBoost TargetBuy$98.00 ➝ $106.00
2/5/2021Piper SandlerBoost TargetOverweight$90.00 ➝ $99.00
2/5/2021Chardan CapitalBoost TargetBuy$81.00 ➝ $97.00
2/5/2021HC WainwrightBoost TargetBuy$90.00 ➝ $95.00
12/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$75.00
12/15/2020UBS GroupInitiated CoverageBuy$95.00
11/24/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$62.00 ➝ $80.00
11/24/2020Cantor FitzgeraldBoost TargetOverweight$58.00 ➝ $80.00
11/24/2020Leerink PartnersLower TargetMarket Perform$35.00 ➝ $34.00
11/19/2020Smith Barney CitigroupInitiated CoverageBuy$90.00
11/17/2020B. RileyBoost TargetBuy ➝ Positive$68.00 ➝ $98.00
11/16/2020Robert W. BairdBoost TargetOutperform$70.00 ➝ $75.00
10/12/2020B. RileyBoost Target$57.00 ➝ $68.00
10/12/2020HC WainwrightReiterated RatingBuy
10/8/2020Piper SandlerBoost Target$80.00 ➝ $90.00
9/17/2020Leerink PartnersBoost TargetMarket Perform$29.00 ➝ $31.00
8/24/2020HC WainwrightReiterated RatingBuy
7/29/2020Chardan CapitalReiterated RatingBuy$81.00
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$62.00
5/10/2020B. RileyReiterated RatingBuy$57.00
5/8/2020Cantor FitzgeraldReiterated RatingBuy$60.00 ➝ $58.00
5/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$58.00
4/15/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$55.00 ➝ $60.00
3/31/2020B. RileyReiterated RatingBuy$57.00
3/24/2020Leerink PartnersUpgradeUnderperform ➝ Market Perform$29.00
3/17/2020The Goldman Sachs GroupInitiated CoverageNeutral$45.00
3/13/2020B. RileyLower TargetBuy$83.00 ➝ $57.00
2/7/2020Jefferies Financial GroupBoost Target$77.00 ➝ $80.00
2/6/2020B. RileyReiterated RatingBuy$83.00
2/6/2020Cantor FitzgeraldBoost TargetNeutral$50.00 ➝ $55.00
1/24/2020B. RileyReiterated RatingBuy$83.00
1/21/2020Leerink PartnersInitiated CoverageUnderperform$32.00
12/12/2019OppenheimerInitiated CoverageHold
12/9/2019Piper Sandler CompaniesBoost TargetOverweight$72.00 ➝ $80.00
11/29/2019Chardan CapitalReiterated RatingBuy$45.00 ➝ $81.00
11/27/2019B. RileyReiterated RatingBuy$59.00 ➝ $83.00
11/26/2019S&P Equity ResearchReiterated RatingBuy
11/26/2019Piper Sandler CompaniesReiterated RatingOverweight$54.00 ➝ $72.00
11/25/2019Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $70.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 8 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 10 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 12 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $18.71
Low: $18.04
High: $18.75

50 Day Range

MA: $19.96
Low: $17.70
High: $21.97

52 Week Range

Now: $18.71
Low: $17.05
High: $39.83

Volume

792,142 shs

Average Volume

1,199,403 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: B. Riley, Bank of America Co., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., HC Wainwright, Morgan Stanley, Piper Sandler, Royal Bank of Canada, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ARWR.

What is the current price target for Arrowhead Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $45.33, suggesting a possible upside of 146.1%. Piper Sandler has the highest price target set, predicting ARWR will reach $62.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $27.00 for Arrowhead Pharmaceuticals in the next year.
View the latest price targets for ARWR.

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARWR.

What other companies compete with Arrowhead Pharmaceuticals?

Other companies that are similar to Arrowhead Pharmaceuticals include Amicus Therapeutics, Perrigo, Ionis Pharmaceuticals, Jazz Pharmaceuticals and Intra-Cellular Therapies. Learn More about companies similar to Arrowhead Pharmaceuticals.

How do I contact Arrowhead Pharmaceuticals' investor relations team?

Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is (626) 304-3400 and its investor relations email address is [email protected]. The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. Learn More about contacing Arrowhead Pharmaceuticals investor relations.